Clinical trials: HEPATITIS C VIRUS CHRONIC INFECTION
Hepatitis C
A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C
This is a Phase 2, multi-center, randomized, open-label study to evaluate the safety, tolerability, and efficacy of Albuferon in subjects with hepatitis C (HEP C) who failed to respond to previous interferon alfa therapy.
- Trial name
- NCT00097435
- Testing
- Albuferon, Ribavirin
- Where
- 8 sites in United States
- Volunteers
- 115 people
- Sponsor
- Human Genome Sciences Inc.
Chronic Hepatitis C
A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects
The primary purpose of this study is to evaluate the safety profile and tolerability of single oral doses of BMS-791325 in subjects with chronic hepatitis C infection
- Trial name
- NCT00664625
- Testing
- BMS-791325
- Where
- 6 sites in United States, Argentina
- Volunteers
- 24 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C Virus Infection
Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection
This primary objectives of the study are to evaluate the safety, tolerability, and efficacy of voxilaprevir (VOX) plus sofosbuvir/velpatasvir (SOF/VEL) fixed dose combination (FDC) ± ribavirin (RBV) in adults with chronic…
- Trial name
- NCT02378935
- Testing
- VOX, SOF/VEL, RBV
- Where
- 34 sites in United States, New Zealand and 1 more
- Volunteers
- 205 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C Virus, Hepatitis C Virus
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection
The purpose of this phase 3, multicenter study is to evaluate the efficacy and safety of ABT-493/ABT-530 in Japanese adults with chronic Hepatitis C Virus (HCV)-infected, HCV direct-acting antiviral agent (DAA) treatment-naïve…
- Trial name
- CERTAIN-1 (NCT02707952)
- Testing
- ABT-493/ABT-530, OBV/PTV/r
- Volunteers
- 295 people
- Sponsor
- AbbVie
Chronic Hepatitis C
A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects
The purpose of this study is to evaluate the relative bioavailability, safety, and tolerability of 3 new formulations of telaprevir relative to the Incivek 375-mg tablets.
- Trial name
- NCT01511432
- Testing
- telaprevir formulation A, telaprevir Formulation B, telaprevir Formulation C
- Where
- 2 sites in United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Chronic Hepatitis C
Re-treatment of HCV Following DAA Failure
HCV infection is treated with oral drugs, termed as 'direct-acting anti-viral agents' (DAAs). In India, four DAAs are available (sofosbuvir [SOF], daclatasvir [DCV], ledipasvir [LDV] and velpatasvir [VEL]).
- Trial name
- NCT03483987
- Testing
- Sof+Ledi+R arm, Sof+Ledi+R+Peg-IFN arm, Sof+Dacla+R arm
- Where
- 2 sites in India
- Volunteers
- 18 people
- Sponsor
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
Chronic Hepatitis C Infection
Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients
This is a multi-centre prospective longitudinal cohort study with the aim of collecting and storing clinical data, patient blood, DNA and PBMCs to examine outcomes related to drug resistance, drug monitoring and host genetics in…
- Trial name
- SEARCH-C (NCT02065999)
- Where
- 2 sites in Australia
- Volunteers
- 100 people
- Sponsor
- Kirby Institute
Hepatitis C
Cognitive Impairments in Chronic Hepatitis C Patients and Potential Reversibility With New Agents (CICHepC)
The overall aim of this study is to evaluate the prevalence of cognitive impairments and brain anomalies in Chronic Hepatitis C infected individuals and to investigate likely changes in cognition and brain structure and function…
- Trial name
- CICHepC (NCT02745132)
- Testing
- Neuropsychological evaluation and Brain MRI
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
Hepatitis C
Impact of Sofosbuvir and Daclatasvir Concentration on HCV RNA
Sofosbuvir plus daclatasvir with or without ribavirin is one of the currently recommended treatment option for chronic hepatitis C.
- Trial name
- NCT03318887
- Testing
- Sofosbuvir/daclatasvir with or without ribavirin
- Where
- France
- Volunteers
- 130 people
- Sponsor
- Hospices Civils de Lyon
Hepatitis C, Chronic
ATHENAS - Retrospective Study of Compliance in Chronic Hepatitis C With Pegylated Interferon Alfa-2b/Ribavirin in Brazil (P05632)
This is a Phase 4, retrospective and observational, multicenter, national (Brazil), open, noncomparative, and nonrandomized study, which does not have visits. This study will be conducted in accordance to Good Clinical Practices.
- Trial name
- ATHENAS (NCT00856024)
- Testing
- Peginterferon alfa-2b, Ribavirin
- Volunteers
- 902 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Chronic, Hepatitis C
Implementation of a Re-engagement Program for Hepatitis C Patients Lost to Follow-up in Argentina.
Hepatitis C virus (HCV) is a leading cause of morbidity and mortality worldwide. This infection continues to represent a major global public health concern.
- Trial name
- NCT06373198
- Testing
- standard of care
- Volunteers
- 800 people
- Sponsor
- Hospital El Cruce
Hepatitis C, Chronic
Eight Weeks of Elbasvir/Grazoprevir in the Treatment of HCV Genotype 4
To evaluate the safety and efficacy of a daily, fixed-dose, 8-week course combination of Elbasvir/Grazoprevir in treatment-naïve, non-cirrhotic patients who are mono-infected with hepatitis C, genotype 4.
- Trial name
- ELEGANT-4 (NCT03578640)
- Testing
- Elbasvir, Grazoprevir 50-100Mg Oral Tablet
- Where
- Saudi Arabia
- Volunteers
- 30 people
- Sponsor
- King Fahad Medical City
Chronic Hepatitis C
Pharmacogenomics Study on IL28B Genetic Variants in Chinese Children With Hepatitis C Virus Infection
The aim of this study is to investigate the relationships between interleukin 28B genetic variants and the response to treatment of chronic hepatitis C in Chinese children.
- Trial name
- NCT01607021
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Beijing 302 Hospital
Chronic Hepatitis C
S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C
This study will examine the effectiveness of S-adenosyl methionine (SAMe) in combination with peginterferon and ribavirin for treating hepatitis C virus.
- Trial name
- NCT00475176
- Testing
- Peginterferon alfa-2a, Ribavirin, S-adenosyl methionine for Chronic Liver Disease
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis c, Metabolic Syndrome
Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination
The purpose of the study is to determine if statin can affect the clinical outcome of chronic hepatitis C patients receiving Sofosbuvir/Daclatasvir/Ribavirin combination
- Trial name
- NCT03490097
- Testing
- Simvastatin 10mg, sofosbuvir plus daclatasvir
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Ain Shams University
Hepatitis C, Chronic
A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials
This open-label, non-randomized, single arm study will provide treatment or re-treatment with Pegasys (peginterferon alfa-2a) as monotherapy or in combination with Copegus (ribavirin) to patients with chronic hepatitis C…
- Trial name
- NCT01853254
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- 67 sites in United States, Australia and 9 more
- Volunteers
- 272 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C
Effect of Teleprevir in Triple Therapy on Intrahepatic Immunological Mechanisms
Chronic hepatitis C infection (HCV) is a disease that affects worldwide about 170 million people. The previous standard of care therapy of chronic HCV patients consists of pegylated-IFN-α combined with ribavirin, and results in…
- Trial name
- ETIM (NCT01641094)
- Where
- 2 sites in Netherlands
- Volunteers
- 20 people
- Sponsor
- Foundation for Liver Research
Hepatitis C, Chronic, Liver Diseases
Cellular Immune Responses in the Liver in Chronic Hepatitis C (CHC) Patients
In order to persist in the liver, HCV has numerous nonspecific and specific strategies to overcome the immunity of the host. The crucial step in the establishment of viral persistence and chronic hepatitis is the avoidance of…
- Conditions
- Hepatitis C, Chronic, Liver Diseases, Virus Diseases
- Trial name
- NCT01062659
- Where
- Germany
- Sponsor
- University of Ulm
Chronic Hepatitis C Infection
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
This phase 2b study will evaluate the efficacy and safety of 16 and 24 weeks of response-guided duration of therapy with GS-9190 and GS-9256 in combination with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®).
- Trial name
- NCT01225380
- Testing
- GS-9190, GS-9256, Pegasys®
- Where
- 114 sites in United States, Austria and 9 more
- Volunteers
- 324 people
- Sponsor
- Gilead Sciences
Hepatitis C
DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral)
The purpose of the study is to examine whether patients who have acute or early chronic hepatitis C virus (HCV) infection can be treated effectively and safely with an interferon-sparing regimen that combines a new direct acting…
- Trial name
- DARE-C II (NCT02156570)
- Testing
- Sofosbuvir and ribavirin
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 20 people
- Sponsor
- Kirby Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.